171 related articles for article (PubMed ID: 38914825)
1. Targeting senescence with SGLT2 inhibitors.
Le Bras A
Lab Anim (NY); 2024 Jul; 53(7):176. PubMed ID: 38914825
[No Abstract] [Full Text] [Related]
2. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
Vallon V; Thomson SC
Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
[No Abstract] [Full Text] [Related]
3. Editorial to the
Lymperopoulos A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108037
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
5. More CREDENCE for SGLT2 Inhibition.
Verma S; Bhatt DL
Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
[No Abstract] [Full Text] [Related]
6. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
Kumar S; Khatik GL; Mittal A
Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
[TBL] [Abstract][Full Text] [Related]
7. The growing clinical effect of SGLT2 inhibitors.
Del Prato S
Lancet Diabetes Endocrinol; 2023 Apr; 11(4):218-219. PubMed ID: 36878241
[No Abstract] [Full Text] [Related]
8. SGLT2 inhibitors: not every drug has the same effect.
Staruschenko A
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073
[No Abstract] [Full Text] [Related]
9. GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.
Aroda VR; Billings LK
J Am Coll Cardiol; 2023 Aug; 82(6):526-528. PubMed ID: 37532423
[No Abstract] [Full Text] [Related]
10. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
Pandey J; Tamrakar AK
Expert Opin Ther Pat; 2019 May; 29(5):369-384. PubMed ID: 31026402
[TBL] [Abstract][Full Text] [Related]
11. Editorial for the
Lymperopoulos A
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069186
[TBL] [Abstract][Full Text] [Related]
12. Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors.
Fender AC; Dobrev D
Naunyn Schmiedebergs Arch Pharmacol; 2023 Apr; 396(4):589-592. PubMed ID: 36943455
[No Abstract] [Full Text] [Related]
13. Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes.
Packer M
Diabetes Obes Metab; 2023 May; 25(5):1143-1146. PubMed ID: 36583283
[No Abstract] [Full Text] [Related]
14. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Savvanis S; Antoniou VK; Memi E
Curr Cardiol Rev; 2020; 16(4):258-265. PubMed ID: 31362691
[TBL] [Abstract][Full Text] [Related]
15. How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors.
Gunasekaran D; Shirali AC
Kidney360; 2023 Sep; 4(9):e1322-e1324. PubMed ID: 37487034
[No Abstract] [Full Text] [Related]
16. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy.
Bhardwaj G; Vakani M; Srivastava A; Patel D; Pappachan A; Murumkar P; Shah H; Shah R; Gupta S
Arch Biochem Biophys; 2021 Oct; 710():108995. PubMed ID: 34289381
[TBL] [Abstract][Full Text] [Related]
17. Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering.
Ceylan AF; Ren SY
Curr Drug Targets; 2018; 19(9):1045-1050. PubMed ID: 29673309
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
[TBL] [Abstract][Full Text] [Related]
19. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
20. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
Haider K; Pathak A; Rohilla A; Haider MR; Ahmad K; Yar MS
Eur J Med Chem; 2019 Dec; 184():111773. PubMed ID: 31630053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
